ACA-28, an ERK MAPK Signaling Modulator, Exerts Anticancer Activity through ROS Induction in Melanoma and Pancreatic Cancer Cells

Teruaki Takasaki,Yasuyuki Hamabe,Kenta Touchi,Golam Iftakhar Khandakar,Takeshi Ueda,Hitoshi Okada,Kazuko Sakai,Kazuto Nishio,Genzoh Tanabe,Reiko Sugiura

DOI: https://doi.org/10.1155/2024/7683793

2024-03-12

Oxidative Medicine and Cellular Longevity

Abstract:The extracellular signal-regulated kinase (ERK) MAPK pathway is dysregulated in various human cancers and is considered an attractive therapeutic target for cancer. Therefore, several inhibitors of this pathway are being developed, and some are already used in the clinic. We have previously identified an anticancer compound, ACA-28, with a unique property to preferentially induce ERK-dependent apoptosis in melanoma cells. To comprehensively understand the biological cellular impact induced by ACA-28, we performed a global gene expression analysis of human melanoma SK-MEL-28 cells exposed to ACA-28 using a DNA microarray. The transcriptome analysis identified nuclear factor erythroid 2-related factor 2 (Nrf2), a master transcription factor that combats oxidative stress, as the most upregulated genetic pathway after ACA-28 treatment. Consistently, ACA-28 showed properties to increase the levels of reactive oxygen species (ROS) as well as Nrf2 protein, which is normally repressed by proteasomal degradation and activated in response to oxidative stresses. Furthermore, the ROS scavenger N-acetyl cysteine significantly attenuated the anticancer activity of ACA-28. Thus, ACA-28 activates Nrf2 signaling and exerts anticancer activity partly via its ROS-stimulating property. Interestingly, human A549 cancer cells with constitutively high levels of Nrf2 protein showed resistance to ACA-28, as compared with SK-MEL-28. Transient overexpression of Nrf2 also increased the resistance of cells to ACA-28, while knockdown of Nrf2 exerted the opposite effect. Thus, upregulation of Nrf2 signaling protects cancer cells from ACA-28-mediated cell death. Notably, the Nrf2 inhibitor ML385 substantially enhanced the cell death-inducing property of ACA-28 in pancreatic cancer cells, T3M4 and PANC-1. Our data suggest that Nrf2 plays a key role in determining cancer cell susceptibility to ACA-28 and provides a novel strategy for cancer therapy to combine the Nrf2 inhibitor and ACA-28.

cell biology

What problem does this paper attempt to address?

The main problem this paper attempts to address is the development of a new anti-cancer strategy by combining an Nrf2 inhibitor with the compound ACA-28 to enhance the killing effect on ERK-dependent cancer cells. Specifically, the study aims to: 1. **Understand the mechanism of action of ACA-28**: Through transcriptome analysis and functional experiments, reveal how ACA-28 induces ROS (reactive oxygen species) to activate the Nrf2 signaling pathway and thereby exert its anti-cancer activity. 2. **Evaluate the role of Nrf2 in the sensitivity of cancer cells to ACA-28**: Investigate whether the expression level of Nrf2 affects the sensitivity of cancer cells to ACA-28, and how Nrf2 overexpression or knockdown alters the cellular response to ACA-28. 3. **Validate the efficacy of combining Nrf2 inhibitors with ACA-28**: Test whether the Nrf2 inhibitor ML385 can enhance the anti-cancer effect of ACA-28 in pancreatic cancer cells, thereby providing a new therapeutic strategy for clinical application. ### Main Findings 1. **ACA-28 induces the Nrf2 signaling pathway through ROS**: - Transcriptome analysis showed that genes related to Nrf2 were significantly upregulated after ACA-28 treatment. - Experimental results indicated that ACA-28 treatment significantly increased intracellular ROS levels and Nrf2 protein levels. - The antioxidant NAC significantly reduced the increase in Nrf2 protein levels induced by ACA-28, thereby weakening its anti-cancer activity. 2. **Nrf2 expression levels affect the sensitivity of cancer cells to ACA-28**: - A549 lung cancer cells with high Nrf2 expression levels exhibited higher resistance to ACA-28. - In HeLa cells, Nrf2 overexpression enhanced resistance to ACA-28, while Nrf2 knockdown increased sensitivity to ACA-28. 3. **Nrf2 inhibitors enhance the anti-cancer effect of ACA-28**: - In pancreatic cancer cell lines T3M4 and PANC-1, the combination of the Nrf2 inhibitor ML385 with ACA-28 significantly increased cell death rates, indicating the potential clinical application value of this combination therapy. ### Conclusion This study reveals the mechanism by which ACA-28 induces the Nrf2 signaling pathway through ROS and demonstrates the critical role of Nrf2 in determining the sensitivity of cancer cells to ACA-28. Additionally, the research provides a novel anti-cancer strategy by combining Nrf2 inhibitors with ACA-28, which may offer a new approach for treating ERK-dependent cancers.

ACA-28, an ERK MAPK Signaling Modulator, Exerts Anticancer Activity through ROS Induction in Melanoma and Pancreatic Cancer Cells

Generation of A Stable Antioxidant Response Element-Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma

MLN2238 exerts its anti-tumor effects <i>via</i> regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma

β2-AR blockade potentiates MEK1/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism

MDA-7/IL-24 inhibits Nrf2-mediated antioxidant response through activation of p38 pathway and inhibition of ERK pathway involved in cancer cell apoptosis

Bis-Cinnamamide Derivatives as APE/Ref-1 Inhibitors for the Treatment of Human Melanoma

Induction of Autophagy and Activation of Sestrin-2/LKB1/AMPK Signalling

Impact of the anti-cancer drug NT157 on tyrosine kinase signalling networks.

Targeting the ERK signaling pathway in cancer therapy

ACP-5862 suppresses esophageal squamous cell carcinoma growth through inducing apoptosis via activation of endoplasmic reticulum stress and ROS production

Data from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks

Rosmarinic acid inhibits proliferation and migration, promotes apoptosis and enhances cisplatin sensitivity of melanoma cells through inhibiting ADAM17/EGFR/AKT/GSK3β axis

Compound 275# Induces Mitochondria-Mediated Apoptosis and Autophagy Initiation in Colorectal Cancer Cells through an Accumulation of Intracellular ROS

Inhibitory activity of acteoside in melanoma via regulation of the ERβ-Ras/Raf1-STAT3 pathway

Combination Treatment With Inhibitors of ERK and Autophagy Enhances Antitumor Activity of Betulinic Acid in Non–small-Cell Lung Cancer In Vivo and In Vitro

Identifying simultaneous inhibition of riboflavin metabolism and MEK as a novel therapeutic strategy for pancreatic cancer

Mitomycin C and its analog trigger cytotoxicity in MCF-7 and K562 cancer cells through the regulation of RAS and MAPK/ERK pathways

N-acylsphingosine amidohydrolase 1 promotes melanoma growth and metastasis by suppressing peroxisome biogenesis-induced ROS production

Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion

Abstract 7273: Small molecule activation of PP2A in the treatment of melanoma